N,cis-2,4-trimethylpiperidine | 15031-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N,cis-2,4-trimethylpiperidine
• 英文别名: (2R,4R)-1,2,4-trimethylpiperidine
• CAS: 15031-98-8；15031-99-9；17286-22-5
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: OHOXUWZWLCKZQT-HTQZYQBOSA-N

物化性质

• 沸点：
  138.0±8.0 °C(Predicted)
• 密度：
  0.807±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Hormone receptor modulators for treating metabolic conditions and disorders
  申请人：ARDELYX, INC.

  公开号：US10793568B2

  公开（公告）日：2020-10-06

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

  本发明涉及用于治疗自身免疫性疾病、肝脏疾病、肠道疾病、肾脏疾病、癌症和其他 FXR 起作用的疾病的 FXR 激活剂，其具有式 (I)：(I)，其中 L1、A、X1、X2、R1、R2 和 R3 如本文所述。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Miller Mark Thomas

  公开号：US20170196862A2

  公开（公告）日：2017-07-13

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
• HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS
  申请人：ARDELYX, INC.

  公开号：US20190233420A1

  公开（公告）日：2019-08-01

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L 1 , A, X 1 , X 2 , R 1 , R 2 , and R 3 are described herein.